INTELLECTUAL PROPERTY

Nexien BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.

You are here: Home About Us

Nexien's Intellectual Property

Nexien has an expanding intellectual property portfolio of exclusive licensed technology, provisional patents, and certain allowed patents, for the use of cannabinoids as pharmaceutical API's for the treatment of targeted medical conditions.

Nexien also has an exclusive license to a patented drug delivery mechanism for the use of cannabinoids in human and veterinary applications. This patented tablet technology offers uniquely accurate and variable dosing within one core tablet design.